it would be great to get Prof E Mercuri to help with the trial in Europe..No Brainer $$$&$
Professor Eugenio Mercuri has already done us a great flavor to present the data at the World Muscle Society Virtual Congress 2020 at Poster session 4, 17.30 –19.30pm BST on Thursday 1 October 2020.
Also, published at NMD Journal... https://www.nmd-journal.com/article/S0960-8966(20)30478-8/fulltext P.284 ATL1102 treatment improves PUL2.0 in non-ambulant boys with Duchenne muscular dystrophy compared to a natural history control G. Tachas; N. Desem; P. Button; G. Coratti; M. Pane;E. Mercuri;
Dr.Charmaine Gittleson had said: "Drugs can fail not because the drug doesn't work but because the experiment you've designed wasn't ideal..."
This is exactly what ANP has been doing..."ANP is addressing the PDCO information requirements and anticipates finalising the trial design with PDCO later in Q3’CY21, ahead of submitting the clinical trial application shortly thereafter for the Phase IIb trial of ATL1102 in non-ambulant DMD patients to be conducted in Europe. ..... ANP through its interactions with PDCO, is looking to ensure that its planned clinical studies will be run in accordance with PDCO expectations for future product approval. "
ANP Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
